NESS06SM reduces body weight with an improved profile relative to SR141716A

Pharmacological Research

Volumn 74, Issue , 2013, Pages 94-108

  Mastinu, Andrea ^a,b   Pira, Marilena ^c,d   Pinna, Gérard Aimè ^d   Pisu, Carla ^c   Casu, Maria Antonietta ^a   Reali, Roberta ^c   Marcello, Stefania ^a   Murineddu, Gabriele ^d   Lazzari, Paolo ^c,d  

^a INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c Neuroscienze PharmaNess Scarl   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

Author keywords

DIO mice; Mood disorders; NESS06SM; Obesity; SR141716A

Indexed keywords

8 CHLORO 1 (2,4 DICHLOROPHENYL) N PIPERIDIN 1 YL 4,5 DIHYDROBENZO 1H 6 OXA CYCLOHEPTA(1,2 C)PYRAZOLE 3 CARBOXAMIDE; ANOREXIGENIC AGENT; APPETITE STIMULANT; CANNABINOID 1 RECEPTOR ANTAGONIST; FATTY ACID SYNTHASE; GLUCOKINASE; N PIPERIDINYL 7 BROMO 1 (2,4 DICHLOROPHENYL) 4,5 DIHYDRO 1H THIENO(2,3 G)INDAZOL 3 CARBOXAMIDE; NESS 0327; NESS 038C6; NESS 06SM; NEUROTROPHIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PYRUVATE KINASE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOBESITY ACTIVITY; ANXIETY; ARTICLE; BLOOD BRAIN BARRIER; CARDIOVASCULAR RISK; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; GENE EXPRESSION PROFILING; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; LIPID METABOLISM; LIQUID SCINTILLATION COUNTING; MALE; MONOAMINERGIC SYSTEM; MOOD DISORDER; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION; WEIGHT REDUCTION;

DIO MICE; MOOD DISORDERS; NESS06SM; OBESITY; SR141716A;

ANIMALS; ANTI-OBESITY AGENTS; BENZOXEPINS; BODY WEIGHT; CANNABINOID RECEPTOR ANTAGONISTS; DIET, HIGH-FAT; FATTY ACID SYNTHASES; GLUCOKINASE; LIVER; MALE; MICE; MICE, INBRED C57BL; OBESITY; PIPERIDINES; PYRAZOLES; PYRUVATE KINASE; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER; SYMPORTERS;

EID: 84884739997     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.06.001     Document Type: Article

References (97)

1. A. Tchernof, and J.P. Després Pathophysiology of human visceral obesity: an update Physiological Reviews 93 2013 359 404
2. M. Maccarrone, V. Gasperi, M.V. Catani, T.A. Diep, E. Dainese, and H.S. Hansen The endocannabinoid system and its relevance for nutrition Annual Review of Nutrition 30 2010 423 440
3. C. Silvestri, A. Ligresti, and V. Di Marzo Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle Reviews in Endocrine and Metabolic Disorders 12 2011 153 162
4. L.K. Miller, and L.A. Devi The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications Pharmacological Reviews 63 2011 461 470
5. M. Solinas, S.R. Goldberg, and D. Piomelli The endocannabinoid system in brain reward processes British Journal of Pharmacology 154 2008 369 383 (Pubitemid 351670594)
6. S.L. Tseng, M.S. Hung, C.P. Chang, J.S. Song, C.L. Tai, and H.H. Chiu Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5- (4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists Journal of Medicinal Chemistry 51 2008 5397 5412
7. Y. Lin, K.S. Shia, W.C. Hsiao, W.P. Hsieh, T.K. Yeh, and S.L. Tseng Biphasic suppression of appetite by cannabinoid CB1 receptor antagonists with distinct functional activities Pharmacological Research 62 2010 337 343
8. S.H. Lee, H.J. Seo, S.H. Lee, M.E. Jung, J.H. Park, and H.J. Park Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity Journal of Medicinal Chemistry 51 2008 7216 7233
9. F.J. Meye, V. Trezza, L.J. Vanderschuren, G.M. Ramakers, and R.A. Adan Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity Molecular Psychiatry 2012 10.1038/mp.2012.145 [Epub ahead of print 16 October]
10. A. Mastinu, M. Pira, L. Pani, G.A. Pinna, and P. Lazzari NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile Behavioural Brain Research 234 2012 192 204
11. F.D. Christopoulou, and D.N. Kiortsis An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity Clinical Pharmacology & Therapeutics 36 2011 10 18
12. L.N. Zhang, Y. Gamo, R. Sinclair, S.E. Mitchell, D.G. Morgan, and J.C. Clapham Effects of chronic oral rimonabant administration on energy budgets of diet-induced obese C57BL/6 mice Obesity 20 2012 954 962
13. J.P. Després, A. Golay, L. Sjöström, and Rimonabant in Obesity-Lipids Study Group Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia The New England Journal of Medicine 353 2005 2121 2134 (Pubitemid 41653104)
14. F.X. Pi-Sunyer, L.J. Aronne, H.M. Heshmati, J. Devin, J. Rosenstock, and RIO-North America Study Group Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial Journal of the American Medical Association 295 2006 761 775 (Pubitemid 43244304)
15. L.F. Van Gaal, A.J. Scheen, A.M. Rissanen, S. Rössner, C. Hanotin, and O. Ziegler Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study European Heart Journal 29 2008 1761 1771 (Pubitemid 352019811)
16. R. Christensen, P.K. Kristensen, E.M. Bartels, H. Bliddal, and A. Astrup Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 370 2007 1706 1713 (Pubitemid 350100788)
17. C.E. Beyer, J.M. Dwyer, M.J. Piesla, B.J. Platt, R. Shen, and Z. Rahman Depression-like phenotype following chronic CB1 receptor antagonism Neurobiology of Disease 39 2010 148 155
18. M.N. Hill, and B.B. Gorzalka The endocannabinoid system and the treatment of mood and anxiety disorders CNS & Neurological Disorders - Drug Targets 8 2009 451 458
19. S. Esteban, and J.A. García-Sevilla Effects induced by cannabinoids on monoaminergic systems in the brain and their implications for psychiatric disorders Progress in Neuro-Psychopharmacology & Biological Psychiatry 38 2012 78 87
20. E. Kirilly, X. Gonda, and G. Bagdy CB1 receptor antagonists: new discoveries leading to new perspectives Acta Physiologica 205 2012 41 60
21. F.J. Bermudez-Silva, M.P. Viveros, J.M. McPartland, and F. Rodriguez de Fonseca The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning Pharmacology Biochemistry and Behavior 95 2010 375 382
22. Y.K. Wu, C.F. Yeh, T.W. Ly, and M.S. Hung A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier Current Topics in Medicinal Chemistry 11 2011 1421 1429
23. S.J. Ward, and R.B. Raffa Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies Obesity 19 2011 1325 1334
24. P.J. McLaughlin Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity Behavioural Pharmacology 23 2012 537 550
25. C. Silvestri, and V. Di Marzo Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders Expert Opinion on Investigational Drugs 21 2012 1309 1322
26. J. Tam, V.K. Vemuri, J. Liu, S. Bátkai, B. Mukhopadhyay, and G. Godlewski Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity Journal of Clinical Investigation 120 2010 2953 2966
27. J.M. Receveur, A. Murray, J.M. Linget, P.K. Nørregaard, M. Cooper, and E. Bjurling Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier Bioorganic & Medicinal Chemistry Letters 20 2010 453 457
28. F.J. Pavón, A. Serrano, V. Pérez-Valero, N. Jagerovic, L. Hernández-Folgado, and F.J. Bermúdez-Silva Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats Journal of Neuroendocrinology 20 Suppl. 1 2008 116 123 (Pubitemid 351552685)
29. A. Fulp, K. Bortoff, H. Seltzman, Y. Zhang, J. Mathews, and R. Snyder Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity Journal of Medicinal Chemistry 55 2012 2820 2834
30. A.R. Stoit, J.H. Lange, A.P. Hartog, E. Ronken, K. Tipker, and H.H. Stuivenberg Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists Chemical and Pharmaceutical Bulletin 50 2002 1109 1113 (Pubitemid 41702075)
31. Y. Zhang, J.P. Burgess, M. Brackeen, A. Gilliam, S.W. Mascarella, and K. Page Conformationally constrained analogues of N-(piperidinyl)-5-(4- chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716): design, synthesis, computational analysis, and biological evaluations Journal of Medicinal Chemistry 51 2008 3526 3539 (Pubitemid 351875008)
32. P. Lazzari, A. Pau, S. Tambaro, B. Asproni, S. Ruiu, and G. Pinna Synthesis and pharmacological evaluation of novel 4-alkyl-5-thien-2′-yl pyrazole carboxamides Central Nervous System Agents in Medicinal Chemistry 12 2012 254 276
33. I. Manca, A. Mastinu, F. Olimpieri, M. Falzoi, M. Sani, and S. Ruiu Novel pyrazole derivatives as neutral CB1 antagonists with significant activity towards food intake European Journal of Medicinal Chemistry 62 2013 256 269
34. G. Murineddu, S. Ruiu, G. Loriga, I. Manca, P. Lazzari, and R. Reali Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2′,4′- dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7] cyclohepta[1,2-c]pyrazole-3-carboxamide Journal of Medicinal Chemistry 48 2005 7351 7362 (Pubitemid 41743649)
35. G. Murineddu, S. Ruiu, J.M. Mussinu, G. Loriga, G.E. Grella, and M.A. Carai Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptors Bioorganic & Medicinal Chemistry 13 2005 3309 3320 (Pubitemid 40462132)
36. Lazzari P, Ruiu S, Pinna GA, Murineddu G. Pharmaceutical compounds. Patent No: US 7,659,407, 2005.
37. Lazzari P, Loriga G, Manca I, Pinna GA, Pani L. Pharmaceutical compounds, US Patent Application No: 2010/0215741, 2010.
38. Lazzari P, Loriga G, Manca I, Pinna GA. Pharmaceutical compound, US Patent Application No: 2010/0,215,759, 2010.
39. Lazzari P, Ruiu S, Pinna GA, Murineddu G, Tricyclic pyrazole derivatives as cannabinoid receptor antagonists. European Patent No: EP 1,602,658, 2011.
40. R.G. Pertwee Inverse agonism and neutral antagonism at cannabinoid CB1 receptors Life Sciences 76 2005 1307 1324
41. R.G. Pertwee The pharmacology of cannabinoid receptors and their ligands: an overview International Journal of Obesity 30 Suppl. 1 2006 S13 S18
42. Greig IR, Ross RA, Pertwee RG. US Patent Application No.: 20,100,022,611, 2010.
43. D.E. Clark In silico prediction of blood-brain barrier permeation Drug Discovery Today 8 2003 927 933 (Pubitemid 37230012)
44. D.E. Clark Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration Journal of Pharmaceutical Sciences 88 1999 815 821 (Pubitemid 29398551)
45. D.E. Clark, and S.D. Pickett Computational methods for the prediction of 'drug-likeness' Drug Discovery Today 5 2000 49 58
46. V.N. Viswanadhan, A.K. Ghose, G.R. Revankar, and R.K. Robins Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics Journal of Chemical Information and Modeling 3 1989 163 172
47. P. Ferrara, J. Apostolakis, and A. Caflisch Evaluation of a fast implicit solvent model for molecular dynamics simulations Proteins 46 2002 24 33 (Pubitemid 34033573)
48. A. Kloska, M. Narajczyk, J. Jakóbkiewicz-Banecka, G. Grynkiewicz, W. Szeja, and M.W. Gabig-Cimińska Synthetic genistein derivatives as modulators of glycosaminoglycan storage Journal of Translational Medicine 10 2012 153
49. M.S. Hung, C.P. Chang, T.C. Li, T.K. Yeh, J.S. Song, and Y. Lin Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl) thiophe n-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist ChemMedChem 5 2010 1439 1443
50. P. Lazzari, A. Sanna, A. Mastinu, S. Cabasino, I. Manca, and L. Pani Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice Behavioural Brain Research 217 2011 432 438
51. P. Lazzari, G. Murineddu, I. Manca, G. Loriga, and G.A. Pinna Myrtanil substituent in 3 position of pyrazole ring determines CB1 agonism of novel 4,5-dihydrobenzo-oxa-cycloheptapyrazole cannabinoids Research Triangle Park, NC, USA International Cannabinoid Research Society. Symposium on the Cannabinoids: Proceedings of the 22nd Annual International Cannabinoid Research Society 2012 July 22-27, Freiburg, Germany 2012 3 18
52. T.C. Rosini, A.S. Silva, and Cd. Moraes Diet-induced obesity: rodent model for the study of obesity-related disorders Revista da Associaç ão Médica Brasileira 58 2012 383 387
53. R. Buettner, J. Schölmerich, and L.C. Bollheimer High-fat diets: modeling the metabolic disorders of human obesity in rodents Obesity 15 2007 798 808 (Pubitemid 46740952)
54. V. Di Marzo, and I. Matias Endocannabinoid control of food intake and energy balance Nature Neuroscience 8 2005 585 589 (Pubitemid 40594198)
55. J.L. Wiley, J.J. Burston, D.C. Leggett, O.O. Alekseeva, R.K. Razdan, and A. Mahadevan CB1 cannabinoid receptor-mediated modulation of food intake in mice British Journal of Pharmacology 145 2005 293 300 (Pubitemid 40896074)
56. L. Bellocchio, P. Lafenêtre, A. Cannich, D. Cota, N. Puente, and P. Grandes Bimodal control of stimulated food intake by the endocannabinoid system Nature Neuroscience 13 2010 281 283
57. S.D. McDonald, E. Pesarchuk, A. Don-Wauchope, H. El Zimaity, and A.C. Holloway Adverse metabolic effects of a hypercaloric, high-fat diet in rodents precede observable changes in body weight Nutrition Research 31 2011 707 714
58. K. Van Proeyen, K. Szlufcik, H. Nielens, K. Pelgrim, L. Deldicque, and M. Hesselink Training in the fasted state improves glucose tolerance during fat-rich diet Journal of Physiology 588 2010 4289 4302
59. H. Rodríguez-Hernández, M. Cervantes-Huerta, M. Rodríguez-Moran, and F. Guerrero-Romero Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet Annals of Hepatology 10 2011 486 492
60. L. Bellocchio, G. Mancini, V. Vicennati, R. Pasquali, and U. Pagotto Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases Current Opinion in Pharmacology 6 2006 586 591 (Pubitemid 44660950)
61. T. Jourdan, L. Demizieux, J. Gresti, L. Djaouti, L. Gaba, and B. Vergès Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants Hepatology 55 2012 790 799
62. D.H. Nam, M.H. Lee, J.E. Kim, H.K. Song, Y.S. Kang, and J.E. Lee Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice Endocrinology 153 2012 1387 1396
63. M.A. Valentino, J.E. Lin, and S.A. Waldman Central and peripheral molecular targets for antiobesity pharmacotherapy Clinical Pharmacology & Therapeutics 87 2010 652 662
64. R.J. Rodgers, M.H. Tschöp, and J.P. Wilding Anti-obesity drugs: past, present and future Disease Models & Mechanisms 5 2012 621 626
65. G.W. Kim, J.E. Lin, M.A. Valentino, F. Colon-Gonzalez, and S.A. Waldman Regulation of appetite to treat obesity Expert Review of Clinical Pharmacology 4 2011 243 259
66. S. Engeli Dysregulation of the endocannabinoid system in obesity Journal of Neuroendocrinology 54 2008 2838 2843
67. S. Engeli Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight Handbook of Experimental Pharmacology 209 2012 357 381
68. T. Jourdan, L. Djaouti, L. Demizieux, J. Gresti, B. Vergès, and P. Degrace CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice Diabetes 59 2010 926 934
69. R. Vettor, and C. Pagano The role of the endocannabinoid system in lipogenesis and fatty acid metabolism Best Practice & Research: Clinical Endocrinology & Metabolism 23 2009 51 63
70. T. Priego, J. Sánchez, C. Picó, and A. Palou Sex-differential expression of metabolism-related genes in response to a high-fat diet Obesity 16 2008 819 826 (Pubitemid 351465638)
71. M. Boizard, X. Le Liepvre, P. Lemarchand, F. Foufelle, P. Ferré, and I. Dugail Obesity-related overexpression of fatty-acid synthase gene in adipose tissue involves sterol regulatory element-binding protein transcription factors Journal of Biological Chemistry 273 1998 29164 29171 (Pubitemid 28507616)
72. W. Zhao, O. Fong, E.S. Muise, J.R. Thompson, D. Weingarth, and S. Qian Genome-wide expression profiling revealed peripheral effects of cannabinoid receptor 1 inverse agonists in improving insulin sensitivity and metabolic parameters Molecular Pharmacology 78 2010 350 359
73. J. Berger, and D.E. Moller The mechanisms of action of PPARs Annual Review of Medicine 26 2002 244 251
74. J.P. Berger, T.E. Akiyama, and P.T. Meinke PPARs: therapeutic targets for metabolic disease Trends in Pharmacological Sciences 26 2005 244 251 (Pubitemid 40603072)
75. A. Batra, and B. Siegmund The role of visceral fat Digital Distribution 30 2012 70 74
76. M.C. Klempel, and K.A. Varady Reliability of leptin, but not adiponectin, as a biomarker for diet-induced weight loss in humans Nutrition Reviews 69 2011 145 154
77. C.S. Mantzoros, F. Magkos, M. Brinkoetter, E. Sienkiewicz, T.A. Dardeno, and S.Y. Kim Leptin in human physiology and pathophysiology American Journal of Physiology - Endocrinology and Metabolism 301 2011 E567 E584
78. J. Thundyil, D. Pavlovski, C.G. Sobey, and T.V. Arumugam Adiponectin receptor signalling in the brain British Journal of Pharmacology 165 2012 313 327
79. K. Kishida, K.K. Kim, T. Funahashi, Y. Matsuzawa, H.C. Kang, and I. Shimomura Relationships between circulating adiponectin levels and fat distribution in obese subjects Journal of Atherosclerosis and Thrombosis 18 2011 592 595
80. B.J. Goldstein, and R. Scalia Adiponectin A novel adipokine linking adipocytes and vascular function Journal of Clinical Endocrinology & Metabolism 89 2004 2563 2568 (Pubitemid 38766332)
81. T. Scherer, and C. Buettner Yin and Yang of hypothalamic insulin and leptin signaling in regulating white adipose tissue metabolism Reviews in Endocrine and Metabolic Disorders 12 2011 235 243
82. I. Hochberg, and Z. Hochberg Expanding the definition of hypothalamic obesity Obesity Reviews 11 2010 709 721
83. P. Cardinal, L. Bellocchio, S. Clark, A. Cannich, M. Klugmann, and B. Lutz Hypothalamic CB1 cannabinoid receptors regulate energy balance in mice Endocrinology 153 2012 4136 4143
84. L. Van Gaal, X. Pi-Sunyer, J.P. Després, C. McCarthy, and A. Scheen Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program Diabetes Care 31 2008 S229 S240
85. P.J. Nathan, B.V. O'Neill, A. Napolitano, and E.T. Bullmore Neuropsychiatric adverse effects of centrally acting antiobesity drugs CNS Neuroscience & Therapeutics 17 2011 490 505
86. E. Takahashi, M. Katayama, K. Niimi, and C. Itakura Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests European Journal of Pharmacology 589 2008 149 156
87. S. Spiga, A. Lintas, M. Migliore, and M. Diana Altered architecture and functional consequences of the mesolimbic dopamine system in cannabis dependence Addiction Biology 15 2010 266 276
88. S. Spiga, A. Lintas, and M. Diana Altered mesolimbic dopamine system in THC dependence Current Neuropharmacology 9 2011 200 204
89. S.N. Umathe, S.S. Manna, and N.S. Jain Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice Behavioural Brain Research 223 2011 125 134
90. R.J. McLaughlin, M.N. Hill, S.S. Dang, S.R. Wainwright, L.A. Galea, and C.J. Hillard Upregulation of CB(1) receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure Behavioural Brain Research 237 2013 333 337
91. S. Dubreucq, S. Kambire, M. Conforzi, M. Metna-Laurent, A. Cannich, and E. Soria-Gomez Cannabinoid type 1 receptors located on single-minded 1-expressing neurons control emotional behaviors Neuroscience 204 2012 230 244
92. E. Ganon-Elazar, and I. Akirav Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress Neuropsychopharmacology 37 2012 456 466
93. A.S. Kristensen, J. Andersen, T.N. Jørgensen, L. Sørensen, J. Eriksen, and C.J. Loland SLC6 neurotransmitter transporters: structure, function, and regulation Pharmacological Reviews 63 2011 585 640
94. Z. Zhao, H.T. Zhang, E. Bootzin, M.J. Millan, and J.M. O'Donnell Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs Neuropsychopharmacology 34 2009 1467 1481
95. B.H. Lee, and Y.K. Kim The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment Psychiatry Investigation 7 2010 231 235
96. S. Chourbaji, C. Brandwein, and P. Gass Altering BDNF expression by genetics and/or environment: impact for emotional and depression-like behaviour in laboratory mice Neuroscience & Biobehavioral Reviews 35 2011 599 611
97. M.J. Willemen, A.K. Mantel-Teeuwisse, Y. Buggy, D. Layton, S.M. Straus, and H.G. Leufkens Reasons for and time to discontinuation of rimonabant therapy: a modified prescription-event monitoring study Drug Safety 35 2012 1147 1158